| Primary |
| Chronic Lymphocytic Leukaemia |
29.3% |
| T-cell Lymphoma |
10.4% |
| Drug Use For Unknown Indication |
9.8% |
| Prophylaxis |
9.8% |
| Product Used For Unknown Indication |
8.8% |
| Premedication |
6.3% |
| T-cell Prolymphocytic Leukaemia |
3.7% |
| Bone Marrow Conditioning Regimen |
2.8% |
| Peripheral T-cell Lymphoma Unspecified |
2.8% |
| Renal Transplant |
2.3% |
| Atrial Fibrillation |
1.7% |
| Antiviral Prophylaxis |
1.5% |
| Immunosuppression |
1.5% |
| Infection Prophylaxis |
1.5% |
| Multiple Sclerosis |
1.5% |
| Diarrhoea |
1.4% |
| T-cell Depletion |
1.4% |
| Antifungal Prophylaxis |
1.2% |
| Hypertension |
1.2% |
| Anaemia |
0.9% |
|
| Pancytopenia |
9.6% |
| Pyrexia |
7.7% |
| Atrial Fibrillation |
6.7% |
| Epstein-barr Virus Infection |
6.7% |
| Sepsis |
6.7% |
| Acute Myeloid Leukaemia |
5.8% |
| Skin Cancer |
5.8% |
| Thrombocytopenia |
5.8% |
| Neutropenia |
4.8% |
| Pancreatitis |
4.8% |
| Pneumonia |
4.8% |
| Skin Reaction |
4.8% |
| Eastern Cooperative Oncology Group Performance Status Worsened |
3.8% |
| Septic Shock |
3.8% |
| Transplant Rejection |
3.8% |
| Cytomegalovirus Infection |
2.9% |
| Death |
2.9% |
| Encephalitis |
2.9% |
| Multi-organ Failure |
2.9% |
| Renal Failure Acute |
2.9% |
|
| Secondary |
| Premedication |
21.2% |
| Prophylaxis |
18.9% |
| Chronic Lymphocytic Leukaemia |
11.3% |
| T-cell Lymphoma |
8.2% |
| Product Used For Unknown Indication |
7.6% |
| Peripheral T-cell Lymphoma Unspecified |
7.1% |
| Drug Use For Unknown Indication |
5.1% |
| T-cell Prolymphocytic Leukaemia |
4.5% |
| B-cell Small Lymphocytic Lymphoma |
4.3% |
| Infection Prophylaxis |
2.5% |
| Immunosuppression |
1.5% |
| Prolymphocytic Leukaemia |
1.5% |
| Diarrhoea |
1.2% |
| Hepatosplenic T-cell Lymphoma |
0.9% |
| Bone Marrow Failure |
0.9% |
| Anaemia |
0.8% |
| Erosive Duodenitis |
0.8% |
| Sinusitis |
0.7% |
| Hypertension |
0.6% |
| Infection |
0.6% |
|
| Urticaria |
13.0% |
| Guillain-barre Syndrome |
9.2% |
| Infection |
9.2% |
| Myelodysplastic Syndrome |
8.7% |
| Swelling Face |
6.5% |
| Pyrexia |
6.0% |
| Epstein-barr Virus Infection |
5.4% |
| B-cell Lymphoma |
4.3% |
| Septic Shock |
4.3% |
| Thrombocytopenia |
4.3% |
| Drug Ineffective |
3.8% |
| Liver Disorder |
3.3% |
| Pancreatitis |
3.3% |
| Tumour Lysis Syndrome |
3.3% |
| Atrial Fibrillation |
2.7% |
| Bronchospasm |
2.7% |
| Tachycardia |
2.7% |
| Tuberculosis |
2.7% |
| Coronary Artery Disease |
2.2% |
| Cytomegalovirus Test Positive |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.0% |
| Premedication |
18.3% |
| Haematological Malignancy |
13.9% |
| Bone Marrow Conditioning Regimen |
10.4% |
| Diffuse Large B-cell Lymphoma |
10.4% |
| Prophylaxis |
10.4% |
| Chronic Lymphocytic Leukaemia |
4.3% |
| Prophylaxis Against Graft Versus Host Disease |
3.5% |
| Infection |
2.6% |
| Osteoporotic Fracture |
1.7% |
| T-cell Lymphoma |
1.7% |
| Acute Lymphocytic Leukaemia |
0.9% |
| Antibiotic Prophylaxis |
0.9% |
| Respiratory Tract Infection |
0.9% |
|
| Toxic Skin Eruption |
34.3% |
| Influenza |
8.6% |
| Vasculitis |
8.6% |
| Angioedema |
5.7% |
| Cardiac Arrest |
5.7% |
| Multi-organ Failure |
5.7% |
| Pneumonia Adenoviral |
5.7% |
| Cardiac Failure |
2.9% |
| Death |
2.9% |
| Nasal Necrosis |
2.9% |
| Pulmonary Fibrosis |
2.9% |
| Renal Impairment |
2.9% |
| Rhinitis |
2.9% |
| Serum Ferritin Increased |
2.9% |
| Tendonitis |
2.9% |
| Venoocclusive Disease |
2.9% |
|
| Interacting |
| Bone Marrow Conditioning Regimen |
44.4% |
| Bone Marrow Transplant |
22.2% |
| Product Used For Unknown Indication |
16.7% |
| Drug Intolerance |
11.1% |
| Plasma Cell Myeloma |
5.6% |
|
|
